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IMPACT OF MECHANICAL LOADING OF OSTEOBLASTS ON
CHONDROCYTES: A NOVEL MURINE MODEL FOR ASSESSING BONE/
CARTILAGE COMMUNICATION
S. Priam 1, X. Houard 1, M. Gosset 1, C. Salvat 1, F. Berenbaum1,2,
C. Jacques 1. 1UR 4 - Univ. Pierre et Marie Curie, Paris, France;
2Rheumatology, AP-HP St-Antoine Hospital, France
Purpose: Osteoarthritis (OA) is characterized by joint degeneration,
leading to a progressive loss of articular cartilage in response to
mechanical and biochemical factors. However, OA is a complex disease
not limited to cartilage degeneration. Indeed, several sets of in vitro
and in vivo experiments suggest that subchondral bone remodeling
could initiate and/or contribute to cartilage loss in OA through a bone/
cartilage interplay. The aim of this study was to demonstrate the
ability of soluble mediators released by loaded osteoblasts to shift the
articular chondrocyte phenotype from a resting to a pro-degradative
phenotype through a novel and unique bone/cartilage communication
model.
Methods: Thanks to a three dimensional (3D) culture model, murine
calvaria osteoblasts were submitted to compression in Biopress Flexercell
plates (1.7 MPa, 1Htz during 24h). Then, media from loaded or unloaded
osteoblasts were used to treat primary mouse articular chondrocytes for
24h. Chondrocyte expression and secretion of matrix metalloproteinases
(MMP-3 and -13), MMPs inhibitors (TIMP-1, -2 and -3) and extracellular
matrix proteins (type II collagen, aggrecan) were analyzed by real time RT-
PCR, ELISA and immunoblotting. Osteoblast conditioned media were then
analyzed by iTRAQ (isobaric tags for relative and absolute quantiﬁcation),
a quantitative proteomic approach.
Results: Media from compressed osteoblast (CM) strongly induced
MMP-3 and -13 chondrocyte mRNA expression (Table). Consistently,
CM also signiﬁcantly stimulated the releases of MMP-3 and -13 by
chondrocytes (respectively 10.60.75 fold, p<0.001, and 6.52.1 fold,
p<0.01 compared to control). In addition, CM enhances TIMP-1
expression whereas it strongly inhibited TIMP-2 and -3 expressions
(Table). Osteoblast conditioned media also affected cartilage matrix
proteins expressions. Indeed, CM downregulated aggrecan and type II
collagen mRNA levels (Table). Effects of CM on cytosolic type II
collagen protein amounts were conﬁrmed by western blot (a decrease
of 319%, p<0.01).
Finally, in order to identify osteoblast soluble mediators responsible for
this chondrocyte phenotype, osteoblast conditioned media were
analyzed by iTRAQ. This advanced and sophisticated new
proteomic technique allowed identiﬁcation of 105 proteins secreted by
osteoblasts among which only 10% were modiﬁed in response to
compression.
Conclusions: These results support the hypothesis that soluble
mediators released by bone cells submitted to a mechanical stress
promote chondrocyte activation leading to the release of pro-degra-
dative mediators. Analysis of these soluble mediators will open a new
area of novel biomarkers relying on abnormal bone-cartilage
communication.Table
Effects of media from uncompressed (UCM) or compressed (CM) osteoblasts on MMPs
compared to control (non-stimulated chondrocytes).
MMP-3 MMP-13 TIMP-1 TIMP
UCM 5.93 (ns) 3.40.4 (ns) 1.50.4 (ns) 0.7
CM 50.914.5 (p<0.001) 18.310.9 (p<0.01) 5.21.6 (p<0.001) 0.5269
INHIBITION OF CYCLOOXYGENASE-2 IMPACTS CHONDROCYTE
HYPERTROPHY
M.J. Caron 1, P.J. Emans 1, M.P. Janssen 1, K. Sanen 1, M.M. Coolsen 1,
L. Voss 1, D.A. Surtel 1, A. Cremers 1, J.-W. Voncken 2, T.J. Welting 1,
L.W. van Rhijn 1. 1Dept. Orthopaedic Surgery, Maastricht Univ. Med. Ctr.,
Maastricht, Netherlands; 2Dept. Molecular Genetics, Maastricht Univ. Med.
Ctr., Maastricht, Netherlands
Purpose: Skeletogenesis and bone fracture healing involve endochondral
ossiﬁcation, a process during which cartilaginous primordia are gradually
replaced by bone tissue. In line with a role for cyclooxygenase-2 (COX-2) in
the endochondral ossiﬁcation process, non-steroidal anti-inﬂammatory
drugs (NSAIDs) were reported to negatively affect bone fracture healing
due to impaired osteogenesis. However, a role for COX-2 activity in the
chondrogenic phase of endochondral ossiﬁcation has not been addressed
before.
Methods: The role of COX-2 was studied during chondrogenic differenti-
ation of ATDC5 cells and rabbit periosteal explants. BMP-2 was used to
increase hypertrophic differentiation and the NSAIDs NS398 and Celecoxib
were applied to speciﬁcally inhibit COX-2 activity. Chondrogenic outcome
was measured by gene- and protein expression analysis, and (immuno)
histochemical stainings. For in vivo evidence skeletally immature NZW
rabbits were treated with Celecoxib (10mg/kg) for 21 days. Growth plate
development was analyzed by histochemistry.
Results: Our data reveal essential cross-talk between COX-2 and BMP-2
during chondrocyte hypertrophic differentiation. BMP-2 mediated chon-
drocyte hypertrophy is associated with increased COX-2 expression and
pharmacological inhibition of COX-2 activity decreased BMP-2 induced
hypertrophic differentiation in independent chondrogenic models in vitro
and ex vivo, while leaving chondrogenesis unaltered. Importantly,
systemic inhibition of COX-2 activity in vivo resulted in signiﬁcantly
decreased growth plate thickness, which could be attributed to impaired
chondrocyte hypertrophic differentiation.
Conclusions: Our ﬁndings demonstrate that COX-2 is an important
executing factor of BMP-2-induced chondrocyte hypertrophy in the
context of endochondral ossiﬁcation. These observations provide a novel
etiological perspective on the adverse effects of NSAIDs on bone fracture
healing and have important implications for the use of NSAIDs during
endochondral skeletal development. In addition, our data provides a novel
strategy to improve the outcome of cartilage regenerative medicine by
decreasing the level of unwanted chondrocyte hypertrophy and ossiﬁca-
tion.
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MIR-29B IS OVEREXPRESSED IN OSTEOARTHRITIC PATIENTS AND
TARGETS TYPE II COLLAGEN.
D. Moulin 1, V. Salone 1, M. Koufany 1, T. Clement 2, P. Netter 1, I. Behm-
Ansmant 2, B. Charpentier 2, C. Branlant 2, J.-Y. Jouzeau 1. 1 Laboratoire de
Physiopathologie et Pharmacologie Articulaires, Vandoeuvre les Nancy,
France; 2UMR 7214 AREMS, Vandoeuvre les Nancy, France
Purpose: MiRNAs are single strand non-coding small (21 to 24 nucle-
otides long) RNAs. They act as post-transcriptional repressors by
blocking translation or enhancing mRNA degradation. In osteoarthritis
cartilage, extracellular matrix synthesis by chondrocytes is disrupted.
This functional abnormality is associated to chondrocyte phenotype, TIMPs and matrix proteins chondrocytes expression. Results are expressed in fold
-2 TIMP-3 Collagen II Aggrecan
0.2 (p<0.01) 0.60.1 (p<0.001) 0.70.3 (ns) 0.70.3 (ns)
1.6 (p<0.001) 0.10.05 (p<0.001) 0.40.1 (p<0.01) 0.20.1(p<0.001)
